Caregiver assessment of quality of life in individuals with genetic developmental and epileptic encephalopathies.

The study is a retrospective caregiver questionnaire, not a prospective clinical assessment or intervention trial, so it cannot show that any treatment improves quality of life. Responses came through patient advocacy organizations and were largely from families self-identifying as White, non-Hispanic/Latino, and above average income, so they do not reflect the wider DEE population. The questionnaire combined items from existing tools, but the combined tool was not specifically validated or shown to be reliable in this cohort. Caregiver reports were de-identified and not checked against medical records or genetic results, so medical information may be incomplete or biased. Only a subset of genetic etiologies was represented, and some disease foundations declined participation. Most participants reported multiple diagnoses, so the effect of any single diagnosis on quality of life cannot be separated.

Do not conclude that reducing seizure frequency will improve quality of life. In this caregiver survey, quality of life did not track seizure frequency or longest seizure-free period; it tracked minimally disrupted days, medication side effects, and diagnosis burden. The study did not test any therapy.